Our findings suggest that ABCC10, a novel cGAMP transporter, drives RTR in cancer cells, highlighting its potential usefulness as a biomarker for predicting RT response and as a target for therapeutic strategies to overcome resistance. Here, ABCC10 is linked to cancer.